Curocell Accelerates Push to Become a Global CAR-T Specialist
Korea’s First CAR-T Product Approval
Demonstrating Capabilities in Development, Manufacturing, Quality, and Clinical Trials
Curocell announced on May 4 that it will accelerate its phase two growth strategy to become a global CAR-T (Chimeric Antigen Receptor T-cell) specialist, following the approval of Korea’s first CAR-T therapy, ‘LIMCARTO Injection’.
Curocell considers this product approval a result of having independently built and validated a full-cycle system for research and development, clinical trials, GMP (Good Manufacturing Practice) production, quality control, regulatory approval, and commercial supply of CAR-T therapies in Korea. Leveraging the full-cycle commercialization capabilities acquired during the development of LIMCARTO, the company plans to focus on global development in advanced markets such as North America and Europe, particularly in next-generation cell and gene therapies including solid tumor and in vivo CAR-T.
In particular, solid tumor CAR-T is a key focus area for Curocell’s phase two growth. Solid tumors are known to pose significant challenges for CAR-T therapy development due to factors such as the tumor microenvironment, antigen heterogeneity, and T-cell infiltration and persistence. However, if successful, they offer considerable market potential and clinical impact. Based on next-generation platform technology aimed at enhancing the efficacy of solid tumor treatments, Curocell plans to validate new therapeutic possibilities in high unmet medical needs such as liver cancer, gastric cancer, pancreatic cancer, and colorectal cancer.
The company is also developing in vivo CAR-T technology as a medium- to long-term growth axis. In vivo CAR-T is a next-generation approach where genetic material or vectors are directly administered to the patient to generate CAR-T cells inside the body. Compared to traditional ex vivo CAR-T, this method has the potential to reduce manufacturing complexity and supply timelines, as well as improve treatment accessibility and scalability—factors that are rapidly attracting the attention of global pharmaceutical and biotech companies.
Curocell believes that early efficacy confirmation in actual patients is critical for establishing global development strategies for CAR-T therapies. As CAR-T therapies are administered in a single dose and can show initial efficacy and safety signals within a relatively short period after administration, it is possible to rapidly assess development potential compared to other types of drugs.
Accordingly, the company plans to quickly secure data on the efficacy of solid tumor and next-generation CAR-T candidates in actual patients through investigator-initiated trials in China, where such clinical research is active. Based on these results, Curocell intends to refine its global commercialization strategies, including follow-up clinical trials, technology transfer, and joint development in advanced markets such as North America and Europe. To enable these investigator-initiated trials, the company is in discussions with local Chinese companies regarding clinical trial execution structures and business models, and is considering how to integrate early efficacy data into its global development plans.
Meanwhile, Curocell is also continuing efforts to expand the indications for LIMCARTO. The company plans to broaden the scope of LIMCARTO development beyond hematologic malignancies such as leukemia to include autoimmune diseases like severe lupus, thereby enhancing the clinical utility and product value of its CD19 CAR-T platform.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Curocell representative stated, "Moving forward, we will secure a stable revenue base through the domestic commercialization of LIMCARTO, while integrating clinical trials in China with development strategies for advanced markets, aiming to grow beyond Korea’s first CAR-T developer into a global cell and gene therapy company."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.